The Influence of a KDT501, a Novel Isohumulone, on Adipocyte Function in Humans

OBJECTIVE: In a phase II clinical trial in nine obese, insulin-resistant humans, we observed that treatment with KDT501, a novel isohumulone drug, increased total and high-molecular weight (HMW) adiponectin in plasma. The objective was to determine whether KDT501 increased adiponectin secretion from...

Descripción completa

Detalles Bibliográficos
Autores principales: Finlin, Brian S., Zhu, Beibei, Kok, Bernard P., Godio, Cristina, Westgate, Philip M., Grayson, Neile, Sims, Robert, Bland, Jeffrey S., Saez, Enrique, Kern, Philip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626816/
https://www.ncbi.nlm.nih.gov/pubmed/29033896
http://dx.doi.org/10.3389/fendo.2017.00255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626816/
https://www.ncbi.nlm.nih.gov/pubmed/29033896
http://dx.doi.org/10.3389/fendo.2017.00255

Ejemplares similares